Localization of apolipoprotein(a) and B-100 in various renal diseases.
suggestion that Lp(a) may have thrombogenic as well as atherogenic properties.
The present study was undertaken to determine the presence of apo(a), apoB-l00, and LDL receptor (LDLR) in renal biopsy specimens by an immunofluorescent technique and to clarify the relationships between the presence of apo(a) and apoB-100 and clinical and histological features.
Methods
Ninety-two patients (49 males, 43 females) with various renal diseases who were admitted and examined by renal biopsy in Niigata University Hospital (34 patients) and its affiliated hospitals (58 patients) between February and July 1991 served as the study group. Patient ages ranged from 9 to 76 years; duration from onset of urinary abnormalities until renal biopsy ranged from 1 month to 26 years. Kidney tissue specimens were obtained from these patients by percutaneous renal biopsy. The relationship between the apolipoprotein staining pattern and clinical or histological features was examined in all subjects. Serum Lp(a) was examined in the 34 patients who were at Niigata University Hospital (4 had minor glomerular abnormalities, 12 had IgA nephropathy, 5 had non-IgA nephropathy, 3 had membranous nephropathy, 2 had membranoproliferative glomerulonephritis, 2 had minimal change nephrotic syndrome, 1 had benign nephrosclerosis, 2 had lupus nephritis, 1 had polyarthritis nodosa, 1 had reflux nephropathy, and 1 had Wegener's granulomatosis). Serum Lp(a) levels ranged from 1.1 mg/dl to 170.8 mg/dl.
In the immunofluorescent microscopy cases, a small piece of a specimen was embedded in OCT (Miles Scientic, Naperville, Illinois, USA) and quickly frozen in dry ice and acetone at -70°C. Cryostat sections were cut 2 to 3 microns thick, and rinsed in phosphate-buffered isotonic saline (PBS, pH 7.2) three times for 15 minutes. Fibrinogen was stained by a direct immunofluorescent method as follows: the sections were incubated with FITC conjugated polyclonal anti-human fibrinogen antibody (Behringer, Germany) for 30 minutes at room temperature, and rinsed three times in PBS for 15 minutes mounted in glycerin. Apo(a), apoB-lOO, and LDLR were stained by an indirect immunofluorescent method. After being covered with mouse monoclonal anti-human apo(a) (Cappel, USA), mouse monoclonal anti-cow LDLR antibody (Amersham, USA), and mouse monoclonal anti-human apoB-100 antibody (JIMRO, Japan), the sections of apo(a) were incubated for 30 minutes at room temperature, and the sections of apoB-100 and LDLR were incubated overnight at 4°C. After washing three times in PBS for 15 minutes, they were incubated for 30 minutes with fluorescein-conjugated rabbit anti-mouse immunoglobulin antisera (DAKO, Denmark), which was preadsorbed in normal human serum. Sections were again washed three times in PBS, mounted in glycerin and observed under a Zeiss Axiophot fluorescent photomicroscope. The specificity of apo(a) antibody was confirmed by Western blot analysis, and there was no cross reactivity with LDL or plasminogen. There was no different staining between the antibody adsorbed with plasminogen prior to the immunofluorescence staining and non-adsorbed antibody. The anti-LDLR may recognize the cell surface or internalized LDLRs [6] . The anti-cow LDLR antibodies are known to cross react with human LDLR [7] . The specificities of apoB-100 and LDLR antibody were confirmed by Western blot analysis, and no cross reactivity was found with other apolipoproteins. The patients were divided into three groups on the basis of immunofluorescent microscopic staining pattern findings of apo(a) and apoB-100 as follows: both apo(a) and apoB-100 positive (Group 1; 38 cases), apo(a) positive only (Group 2; 19 cases), and apo(a) negative (Group 3; 35 cases).
In the light microscopic study cases, renal biopsy specimens were fixed in 50% alcohol-Bouin's mixture (saturated picric acid in 50% ethanol, 40 ml; 35% formalin, 7.5 ml; acetic acid, 2.5 ml), embedded in paraffin, and cut into sections 2 to 3 microns thick. The sections, stained with hematoxylin-eosin, periodic acid Schiff, and periodic acid-methenamine silver stain, were examined under a Zeiss Axiophot light microscope. The mesangial lesion, an increase in cells and/or matrix, was divided into focal and diffuse proliferation. The presence of glomerular adhesions, sclerosis, vascular changes, and interstitial changes was also evaluated. Serum samples were obtained from the patients after 12 hours of fasting. Total cholesterol (TC), triglyceride (TG), uric acid (UA), and total protein (TP) were determined via standard laboratory methods. Lp(a) was determined using an ELISA method [TintElize Lp(a), Biopool, UmeA, Sweden]. Urinary protein excretion (Un) and creatinine clearance (Car) were calculated from 24-hour urine samples.
Statistical analysis was performed using the chi-square test, or Wilcoxon's U-test. A probability of P < 0.05 was regarded as significant.
Results
Apo(a), apoB-100, and LDLR were demonstrated to have a granular pattern in the glomeruli, mainly in the mesangial area and occasionally along capillary loops, as shown in Figure 1 . In two control tissue specimens from patients with non-tumorous renal cell carcinoma, two cases of Bartter's syndrome, three cases of thin basement membrane disease (TBD), no apo(a), apoB-lOO, or LDLR were detected in the glomeruli. These controls had normal renal function, no glomerular and interstitial injury, and no proteinuria; three cases of TBD only had microscopic hematuria. Among the patients with primary gbmerulonephritis, 6 had minor glomerular abnormalities, 39 had IgA nephropathy (IgAGN), 9 had non-IgAGN, 7 had membranous nephropathy, 2 had membranoproliferative glomerulonephritis, 6 had minimal change nephrotic syndrome, 1 had endocapillary proliferative glomerulonephritis, and 2 had be- nign nephrosclerosis. Among those with secondary glomerular diseases, 8 had diabetic glomerubosclerosis, 7 had lupus nephritis, 2 had Henoch-Schonlein purpura nephritis, 1 had polyarthritis nodosa, 1 had reflux nephropathy, and 1 had Wegener's granulomatosis, as shown in Table 1 . The relationship between apolipoprotein staining and histological findings is shown in Table 2 . Glomerulosclerosis was observed in 70% of Group 1 patients, in 68% of Group 2, and in 32% of Group 3.
Significant differences were found between Groups 1 and 3, and between Groups 2 and 3 (P < 0.01 and P < 0.05, respectively). Interstitial scarring was present in 75% of Group 1 patients, in 68% of Group 2, and in 44% of Group 3. There was a significant difference between Groups 1 and 3 (P < 0.01). There was no relationship between glomerular apolipoprotein staining and fibrinogen deposition in glomeruli or other histological findings. Table 3 shows the relationship between apo(a) and apoB-100 and clinical features. UP in Group 1, 2.6 5.0 glday, and in Group 2, 2.9 3.9 glday, was significantly greater than in Group 3,0.9 1,4 glday (P <0.01 and P < 0.05, respectively). TP in Group 1 (6.2 0.9 g/dl) was significantly lower than in Group 3 (7.0 0.7 g/dl; P < 0.01). The serum level of Lp(a) in Group I (N = 15; 47.8 43.3 mgldl) was significantly higher than in Group 3 (N = 14; 13.2 9.5 mgldl; P < 0.01). There were no significant differences in age, Cc, UA, TC, TG, or disease duration among the three groups.
As shown in Figure 2 , LDLR was detected in 63% (24 of 38) of Group 1 patients. In Group 2, LDLR was detected in 15% (3 of 19) and in Group 3 in 20% (7 of 35). Apo(a) and apoB-100 were co-localized in glomeruli mainly in the mesangial area and occasionally in capillary ioops.
There was a significant relationship between LDLR staining and proteinuria; LDLR positive cases had more severe proteinuria than negative cases (2.9 5.5 g/day vs. 1.7 2.9 g/day; P < 0.05). However, there was no significant relationship between LDLR staining and TC [259.4 111.9 mg/dl (LDLR positive) vs. 207.2 71.3 mg/dl (LDLR negative); P < 0.1].
Discussion
Both Lp(a) and apo(a) compete with plasminogen for binding to endothelial plasminogen receptors [8, 9] . The binding of plasminogen to receptor at the endothelial layer of blood vessels is thought to facilitate the interconversion of plasminogen to active protease plasmin. Lp(a) and apo(a) inhibit the tissue plasminogen activator-mediated activation of plasminogen. Another feature of Lp(a) is its ability to bind to proteolytically degraded fibrin [10] . Therefore, Lp(a) may interfere with an essential step in fibrinolysis and hence modulate the clotting process. Glomerular fibrin deposition is a prominent feature of the coagulation abnormalities in aggressive proliferative gbmerulonephritis, and is considered to be one factor leading to clinical progression [11] . Apo(a) deposition in glomeruli might affect the coagulation system, thereby mediating the progression of renal damage. However, there was no relationship between apo(a) and fibrinogen deposition in glomeruli, since anti-fibrinogen antibody utilized in this study recognizes fibrinogen and other breakdown products of fibrinogen, but does not recognize fibrin.
Groups I and 2 had more sclerotic glomeruli and tubulointerstitial changes than Group 3. Lp(a) is able to bind fibronectin [121, which is detected much more commonly in the mesangial proliferative region than the nonproliferative region of glomeruli [13] . Lp(a) present in glomeruli might reflect a larger amount of fibronectin than if Lp(a) were absent in glomeruli. It can be expected that an increase in the synthesis or a disturbance in the degradation of fibronectin would cause the expansion of extracellular matrix, glomeruboscierosis, and interstitial changes.
Recently, Lp(a) has been shown to inhibit the generation of transforming growth factor beta (TGF-f3). Lp(a) might inhibit the activation of latent TGF-f3 by competing with the binding of plasminogen to cell or matrix surfaces [14] . TGF-f31 is now recognized to be a multifunctional cytokine with both growth promoting and growth inhibiting activities in various cell types. TGF-/ acted as an inhibitory regulator of mesangial cell proliferation. On the other hand, TGF-p promotes mesangial cells to produce mesangial matrix, that is, collagen, fibronectin, and laminin [15] . TGF-f31 was produced by smooth muscle cells during repairing of artery injury [16] . Therefore, apo(a) deposited in the mesangial area may interfere with repairing injured cells or tissue.
Proteinuria is a key feature of progressive renal diseases, often being used as a parameter of the effect of treatment or experimental manipulations. There is a strong relation between proteinuria and plasma cholesterol concentration [17] . There have only been a few reports on proteinuria and serum Lp(a) concentrations [18, 19] . In this study, we demonstrated that apo(a) and apoB-lOO accumulate in glomeruli in the setting of various renal diseases. We also showed that apo(a) and apoB-100 co-localized in glomeruli. This indicates localization of lipoprotein-like particles in glomeruli, since both apoproteins are present in Lp(a), usually as a disulfide-linked complex. That both apo(a) and apoB-100 are immunologically detectable in glomeruli suggests that major Lp(a) components accumulate extracellularly instead of being digested within cells. But in Group 2, which comprised only 20% of all our cases, apo(a) alone was deposited in gbomeruli. These findings suggest that Lp(a) might be degraded in gbomeruli. However, apo(a) and apoB-100 could be subject to alterations related to the tissue preparation process that would render their antigenic determinants unavailable for binding with the antibody, and in addition, 29.6 32.9 (N = 5) 13.2 9.5 (N = 14) Disease duration 5.6 6.5 6.2 9.1 4.2 6.2 years Abbreviations are: Car, creatinine clearance; UA, uric acid; TP, total protein; TC, total cholesterol; TG, triglyceride; Lp(a), lipoprotein(a); NS, not significant. U, in Groups 1 and 2 was significantly greater than in Group 3. UA in Group 1 was significantly higher than in Group 3. TP in Group 1 and 2 was significantly lower than in Group 3. The serum level of Lp(a) in Group I was significantly higher than in Group 3. P < 0.01 compared with Group 3 b P < 0.05 compared with Group 3 the clinical parameters in Group 2 are similar to those in Group 1. Therefore, it cannot be said with certainty that apoB-100 is not present in Group 2. This study involved the use of a mouse monoclonal anti-human apo(a) antibody, and it might not detect all apo(a) isoforms [5, 20, 211 ; therefore, it is possible that the apo(a) negative group could actually have apo(a) present with different antigenic determinants not recognized by the monoclonal antibody used. Serum levels of Lp(a) in Group 1 were higher than in Group 3. Proteinuria in Group 1 was greater than in Group 3. These findings suggest that proteinuria affects the serum Lp(a) concentration, and that Lp(a) might deposit in glomeruli. The mechanism of apo(a) deposition in glomeruli is unknown. However, some mechanisms have been postulated.
The site and mechanism of Lp(a) catabolism is still under debate, but the LDL receptor pathway seems to be emerging as a major route [22] . First, LDLR was shown in glomeruli in 63% of Group 1 patients, but only in 15% of Group 2 and 20% of Group 3. These findings suggest that some apo(a) bound with apoB-100, while the remaining apo(a) without apoB-100 might enter glomeruli via LDLRs, since mesangial and epithelial cells possess LDLRs [23, 24] . In this study, LDLR positive cases had more severe proteinuria than negative cases, but there was no significant relationship between LDLR staining and TC. The LDL pathway functions to maintian a constant concentration of cellular cholesterol. Additionally, it is suggested that arachidonic acid obtains access to cells via LDLR; therefore, prostaglandin formation is directly linked to this pathway [25] . LDLR present in glomeruli might somewhat relate to arachidonate metabolism. In the kidney, eicosanoids are involved in the regulation of renal vascular tone and tubular function under normal conditions, and in mediating alternations in glomerular function during injury [261. Moreover, overexpression of LDLR in glomerular diseases might lead to accelerated catabolism of Lp(a) [22] . Second, although scavenger receptors were not revealed in glomeruli, the cases without the present of LDLR in Groups 1 and 2 might enter glomeruli via scavenger receptors. Mouse macrophages take up recombinant apo(a) via scavenger receptors and degradation of apo(a) [27] . Third, serum Lp(a) is trapped in glomeruli, and apo(a) might bind to fibronectin or glycosaminoglycans around the mesangium [12] . Michael et al described that the mesangium has a pathway to remove macromolecules from the mesangial zone to the hilum of the glomerulus [281. Local intraglomerular hemodynamic changes may modulate uptake and disposal of macromolecules, Lp(a), and Lp(a) was present in mesangium. However, this trapped Lp(a) could then be subject to oxidative modification, especially under conditions of local activation of mesangial cells and monocytes. Oxidized Lp(a) has the potential to be pathologically significant, which leads to its uptake by macrophages [29] . The major site of apo(a) synthesis is the liver, and small amounts of mRNA have also been detected in brain and testis [301, but there have been no reports of Lp(a) production in the kidney, However, it is unknown whether apo(a) synthesis might occur in glomeruli in various renal disease states.
Serum and liver samples from various specimens were analyzed for the presence of Lp(a), but only humans, primates, and hedgehogs were found to express apo(a) [31, 32] . The rat and the mouse, the most common animal models available for experimentation, do not express apo(a). Treatment of hyperlipidemia by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in the obese Zucker rat [331, or by clofibric acid in the rat 5/6 nephrectomy model, reduces glomerular injury [34] .
Although there has been one report of reduced renal injury [35] , lipid lowering agents in human renal diseases do not always ameliorate renal damage. These findings suggest that Lp(a) might have some effects on human renal diseases, in contrast to experimental animal models.
Lp(a) is a qualitative and quantitative genetic trait. Around 70% of normal people have serum Lp(a) levels below 25 mg/dl.
Utermann has postulated that there is a highly significant association between the Lp(a) concentration in serum and the different apo(a) phenotypes on SDS-PAGE. It is estimated that only 40% of the plasma level of Lp(a) is under the control of the apo(a) gene, indicating that more than half of the Lp(a) level is determined by the action of other genes and/or environmental factors [5] . However, in renal diseases, serum Lp(a) might change according to proteinuria. For example, 10 mg/dl of serum Lp(a) without proteinuria might increase to 20 mg/dl when proteinuria is overt, and Lp(a) might then deposit in glomeruli. Therefore, it might be prudent to recommend decreasing serum Lp(a) levels in renal diseases. Whether the lowering of high Lp(a) plasma levels beneficially influences the progression of renal diseases is unknown.
In conclusion, this is the first study showing a significant relationship between Lp(a) serum levels and apo(a) and apoB-100 presence in glomeruli. Our studies imply that Lp(a) enters the mesangial area and capillary loops, where co-localization of apo(a) and apoB-l00 can be shown by immunohistochemical methods. Lp(a) hyperlipidemia and apo(a) deposition in glomernh may participate in the persistence and progression of renal damage in all types of immunologically and nonimmunologically mediated renal diseases. More detailed studies will be required to evaluate the present data and to finally elucidate the role of Lp(a) in renal diseases.
